SRZN Surrozen, Inc./DE
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%
Returns
ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $5.00M | $5.00M | $528,000 | $983,000 | $983,000 | $983,000 | $655,000 |
| R&D expense | $10.84M | $8.48M | $9.33M | $8.99M | $7.77M | $6.04M | $6.56M | $5.35M |
| SG&A expense | $6.80M | $6.89M | $6.13M | $4.18M | $4.09M | $3.96M | $3.98M | $3.90M |
| Operating income | -$17.64M | -$10.37M | -$10.46M | -$12.64M | -$10.88M | -$9.02M | -$9.55M | -$8.59M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$129.72M | $50.18M | -$127.50M | -$183.16M | -$71.64M | $39.75M | -$26.97M | -$28.04M |
| EBITDA | -$17.59M | -$10.32M | -$10.39M | -$12.59M | -$10.82M | -$8.88M | -$9.26M | -$8.27M |
| EPS (basic) | -11.02 | 2.75 | -11.65 | — | -8.36 | 2.55 | -7.43 | — |
| EPS (diluted) | -11.02 | -0.41 | -11.65 | — | -8.36 | 2.55 | -7.43 | — |
| Weighted avg. shares (diluted) | 11,774 | 23.15M | 10,949 | — | 8,571 | 8.54M | 3,628 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $100.35M | $102.04M | $106.91M | $89.25M | $81.33M | $90.39M | $101.64M | $35.25M |
| Receivables | — | $5.00M | $5.00M | $0 | $2.32M | $2.32M | $2.13M | $2.04M |
| Current assets | $102.89M | $109.40M | $113.95M | $91.56M | $85.86M | $94.23M | $106.01M | $38.93M |
| PP&E, net | $432,000 | $456,000 | $488,000 | $433,000 | $139,000 | $176,000 | $295,000 | $562,000 |
| Total assets | $109.03M | $115.61M | $120.71M | $98.73M | $94.05M | $102.70M | $114.83M | $48.47M |
| Current liabilities | $13.61M | $9.01M | $9.56M | $9.93M | $6.53M | $5.74M | $10.58M | $7.32M |
| Total liabilities | $444.66M | $334.27M | $398.86M | $286.49M | $117.56M | $55.58M | $109.16M | $69.85M |
| Shareholders' equity | -$335.62M | -$218.66M | -$278.15M | -$187.76M | -$23.52M | $47.11M | $5.67M | -$21.38M |
| Shares outstanding | 12.03M | 11.75M | 11.49M | 9.78M | 8.57M | 8.57M | 8.49M | 3.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.83M | -$7.42M | -$12.49M | -$5.81M | -$9.04M | -$6.11M | -$9.28M | $3.48M |
| Capital expenditure | $27,000 | $19,000 | $120,000 | $59,000 | $24,000 | $18,000 | $27,000 | $19,000 |
| Free cash flow | -$4.86M | -$7.43M | -$12.62M | -$5.87M | -$9.06M | -$6.13M | -$9.31M | $3.46M |
| Investing cash flow | -$27,000 | -$19,000 | -$120,000 | -$59,000 | -$24,000 | -$18,000 | -$27,000 | -$19,000 |
| Financing cash flow | $3.17M | $2.51M | $30.28M | $13.78M | $9,000 | -$5.12M | $76.39M | $91,000 |
| Depreciation & amortization | $51,000 | $51,000 | $65,000 | $45,000 | $61,000 | $137,000 | $294,000 | $322,000 |
| Stock-based compensation | $2.93M | $2.89M | $2.10M | $1.00M | $1.00M | $994,000 | $834,000 | $900,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.